MedTrace Logo

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

NCT04575415 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 272

Last updated 2020-10-20

No results posted yet for this study

Summary

This study is a prospective, multicenter, real-world study to investigate the efficacy and safety of bevacizumab plus epidermal growth factor (EGFR) Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB/IV EGFR-mutant Non-small Cell Lung Cancer.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle

DRUG

Erlotinib

Erlotinib 150mg, orally once a day

DRUG

Gefitinib

Gefitinib 250mg, orally once a day

DRUG

Icotinib

Icotinib 125mg three times a day

DRUG

Afatinib

Afatinib 40 mg or clinical routine dose once daily

DRUG

Dacomitinib

Dacomitinib 45mg or clinical routine dose once daily

DRUG

Osimertinib

Osimertinib 80 mg once daily

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Qing Zhou, PhD · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2023-05-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575415 on ClinicalTrials.gov